1. Home
  2. CET vs IOVA Comparison

CET vs IOVA Comparison

Compare CET & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

N/A

Current Price

$53.36

Market Cap

1.6B

Sector

Finance

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.65

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
IOVA
Founded
1929
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
CET
IOVA
Price
$53.36
$3.65
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$9.00
AVG Volume (30 Days)
38.9K
14.3M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
5.12%
N/A
EPS Growth
N/A
14.84
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$47.74
Revenue Next Year
N/A
$40.31
P/E Ratio
$6.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.77
$1.64
52 Week High
$54.28
$5.63

Technical Indicators

Market Signals
Indicator
CET
IOVA
Relative Strength Index (RSI) 58.03 50.41
Support Level $50.64 $2.05
Resistance Level $53.88 $4.27
Average True Range (ATR) 0.70 0.25
MACD -0.10 0.01
Stochastic Oscillator 54.68 42.61

Price Performance

Historical Comparison
CET
IOVA

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: